• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Multi-objective control to schedule therapies for acute viral infections.用于安排急性病毒感染治疗方案的多目标控制
J Math Biol. 2025 Feb 4;90(2):25. doi: 10.1007/s00285-025-02188-y.
2
A theory for viral rebound after antiviral treatment: A study case for SARS-CoV-2.抗病毒治疗后病毒反弹的理论:以严重急性呼吸综合征冠状病毒2为例的研究
Math Biosci. 2025 Jan;379:109339. doi: 10.1016/j.mbs.2024.109339. Epub 2024 Nov 20.
3
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.免疫功能低下宿主持续性 SARS-CoV-2 感染的晚期抗病毒治疗效果。
J Virol. 2024 Sep 17;98(9):e0090524. doi: 10.1128/jvi.00905-24. Epub 2024 Aug 29.
4
Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.奥密克戎变异株流行期间中国住院 COVID-19 感染者中莫努匹韦、阿兹夫定和奈玛特韦/利托那韦对比死亡率和病毒清除的真实世界疗效:一项回顾性队列研究。
Diagn Microbiol Infect Dis. 2024 Aug;109(4):116353. doi: 10.1016/j.diagmicrobio.2024.116353. Epub 2024 May 18.
5
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.模型表明,奈玛特韦-利托那韦治疗后SARS-CoV-2的反弹是由靶细胞保留以及病毒清除不完全共同驱动的。
J Virol. 2025 Mar 18;99(3):e0162324. doi: 10.1128/jvi.01623-24. Epub 2025 Feb 4.
6
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.莫努匹拉韦和奈玛特韦对重症COVID-19模型中SARS-CoV-2基因组多样性的影响。
Microbiol Spectr. 2025 May 6;13(5):e0182924. doi: 10.1128/spectrum.01829-24. Epub 2025 Mar 25.
7
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.评估在接受抗 CD20 抗体治疗的 B 细胞淋巴瘤 COVID-19 患者中,使用抗 SARS-CoV-2 单克隆抗体和长期使用抗病毒药物期间,病毒持续脱落的风险因素。
BMC Infect Dis. 2024 Jul 22;24(1):715. doi: 10.1186/s12879-024-09631-3.
8
Modelling the effectiveness of antiviral treatment strategies to prevent household transmission of acute respiratory viruses.模拟抗病毒治疗策略预防急性呼吸道病毒家庭传播的有效性。
PLoS Comput Biol. 2024 Dec 5;20(12):e1012573. doi: 10.1371/journal.pcbi.1012573. eCollection 2024 Dec.
9
A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.一种用于比较 SARS-CoV-2、MERS-CoV 和 SARS-CoV 宿主内动力学的定量模型,为 SARS-CoV-2 的发病机制和治疗提供了新的见解。
PLoS Biol. 2021 Mar 22;19(3):e3001128. doi: 10.1371/journal.pbio.3001128. eCollection 2021 Mar.
10
Viral Kinetics Model of SARS-CoV-2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection.SARS-CoV-2 感染的病毒动力学模型为药物发现、临床剂量和方案选择提供信息。
Clin Pharmacol Ther. 2024 Sep;116(3):757-769. doi: 10.1002/cpt.3267. Epub 2024 Apr 26.

本文引用的文献

1
Minimizing the epidemic final size while containing the infected peak prevalence in SIR systems.在SIR系统中控制感染峰值患病率的同时,使疫情最终规模最小化。
Automatica (Oxf). 2022 Oct;144:110496. doi: 10.1016/j.automatica.2022.110496. Epub 2022 Jul 30.
2
In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness.SARS-CoV-2 感染的体内动力学及其与个体传染性的关系。
Proc Natl Acad Sci U S A. 2021 Dec 7;118(49). doi: 10.1073/pnas.2111477118.
3
Dynamical characterization of antiviral effects in COVID-19.新型冠状病毒肺炎抗病毒作用的动力学特征
Annu Rev Control. 2021;52:587-601. doi: 10.1016/j.arcontrol.2021.05.001. Epub 2021 May 28.
4
Characterization of SARS-CoV-2 dynamics in the host.新冠病毒在宿主体内的动态特征
Annu Rev Control. 2020;50:457-468. doi: 10.1016/j.arcontrol.2020.09.008. Epub 2020 Oct 6.
5
In-host Mathematical Modelling of COVID-19 in Humans.新冠病毒在人体内的宿主数学建模
Annu Rev Control. 2020;50:448-456. doi: 10.1016/j.arcontrol.2020.09.006. Epub 2020 Sep 30.
6
Virological assessment of hospitalized patients with COVID-2019.住院 COVID-19 患者的病毒学评估。
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
7
Reproduction numbers of infectious disease models.传染病模型的繁殖数。
Infect Dis Model. 2017 Jun 29;2(3):288-303. doi: 10.1016/j.idm.2017.06.002. eCollection 2017 Aug.
8
In-host modeling.宿主体内建模
Infect Dis Model. 2017 Apr 29;2(2):188-202. doi: 10.1016/j.idm.2017.04.002. eCollection 2017 May.
9
The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment.宿主体内流感病毒控制机制影响基于模型的抗病毒治疗评估与预测。
Viruses. 2017 Jul 26;9(8):197. doi: 10.3390/v9080197.
10
Modelling original antigenic sin in dengue viral infection.登革病毒感染中原发性抗原罪的建模
Math Med Biol. 2018 Jun 13;35(2):257-272. doi: 10.1093/imammb/dqx002.

用于安排急性病毒感染治疗方案的多目标控制

Multi-objective control to schedule therapies for acute viral infections.

作者信息

Perez Mara, Actis Marcelo, Sanchez Ignacio, Hernandez-Vargas Esteban A, González Alejandro H

机构信息

Instituto Tecnológico para el Desarrollo de la Industria Química (INTEC), Universidad Nacional del Litoral (UNL) and Consejo Nacional de Investigaciones científicas y técnicas (CONICET), Santa Fe, Argentina.

Facultad de Ingeniería Química (FIQ), Universidad Nacional del Litoral (UNL) and Consejo Nacional de Investigaciones científicas y técnicas (CONICET), Santa Fe, Argentina.

出版信息

J Math Biol. 2025 Feb 4;90(2):25. doi: 10.1007/s00285-025-02188-y.

DOI:10.1007/s00285-025-02188-y
PMID:39904788
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12119099/
Abstract

Antiviral therapies can yield different outcomes depending on their scheduling: a highly effective drug may produce treatment results ranging from successful to inconsequential, depending on therapeutic timing, dosing intervals, and dosage. The effectiveness of antiviral therapies can be assessed using mathematical models that describe viral spread within a host. In this work, we conduct a study based on the dynamic characterization of a target-cell model to address a multi-objective control problem aimed at designing highly effective and host-customizable antiviral therapies. These therapies involve finite-time antiviral treatments that minimize the viral load peak and the infection final size until infection clearance, while simultaneously reducing the total amount of drug intake as much as possible. Two optimization-based control strategies are proposed: a fixed-dose and a variable-dose approach. The variable-dose strategy achieves superior performance by explicitly considering the system dynamics in the design of the control. Simulation results, based on an identified model for COVID-19 patients treated with Paxlovid, illustrate the potential benefits of the proposed strategies.

摘要

抗病毒疗法根据其给药方案可能产生不同的结果

一种高效药物可能产生从成功到无关紧要的治疗效果,这取决于治疗时机、给药间隔和剂量。抗病毒疗法的有效性可以使用描述病毒在宿主体内传播的数学模型来评估。在这项工作中,我们基于目标细胞模型的动态特征进行了一项研究,以解决一个多目标控制问题,旨在设计高效且可根据宿主定制的抗病毒疗法。这些疗法涉及有限时间的抗病毒治疗,可在感染清除前将病毒载量峰值和感染最终规模降至最低,同时尽可能减少药物摄入总量。提出了两种基于优化的控制策略:固定剂量和可变剂量方法。可变剂量策略通过在控制设计中明确考虑系统动态来实现卓越性能。基于为接受帕罗韦德治疗的新冠肺炎患者确定的模型的模拟结果,说明了所提出策略的潜在益处。